CN116239691B - 一种抗b7-h3纳米抗体及其应用 - Google Patents
一种抗b7-h3纳米抗体及其应用 Download PDFInfo
- Publication number
- CN116239691B CN116239691B CN202211731515.XA CN202211731515A CN116239691B CN 116239691 B CN116239691 B CN 116239691B CN 202211731515 A CN202211731515 A CN 202211731515A CN 116239691 B CN116239691 B CN 116239691B
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- framework region
- complementarity determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 25
- 101710185679 CD276 antigen Proteins 0.000 claims abstract description 18
- 102100038078 CD276 antigen Human genes 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 71
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 229910000831 Steel Inorganic materials 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000010959 steel Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 6
- 230000014509 gene expression Effects 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 10
- 241000282836 Camelus dromedarius Species 0.000 description 9
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 9
- 102000048770 human CD276 Human genes 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明公开了一种抗B7‑H3纳米抗体及其应用,该抗B7‑H3纳米抗体包括框架区FR和互补决定区CDR,互补决定区CDR包含互补决定区CDR1,互补决定区CDR2和互补决定区CDR3。本发明的抗B7‑H3纳米抗体对B7‑H3具有特异的识别和结合能力,并有望作为治疗性抗体用于各种B7‑H3分子高表达的恶性肿瘤。
Description
技术领域
本发明涉及免疫学领域,具体涉及一种抗B7-H3纳米抗体及其应用。
背景技术
免疫治疗是继手术、化疗和放疗之后的第四种抗肿瘤方式。T细胞通过特异性T细胞受体(TCR)识别肿瘤细胞,成为过继细胞治疗的重要效应细胞。几十年来,研究人员在利用T细胞对抗肿瘤靶点做出了巨大努力。最近免疫检查点封锁取得了巨大的成功,如靶向CTLA-4(细胞毒性t淋巴细胞抗原4)和PD-1/PD-L(程序性细胞死亡1/PD-1配体),促进了癌症的治疗,双特异性抗体(BiAbs)可同时靶向TCR和肿瘤相关抗原(TAA)。针对不同TAAs的双特异性抗体,包括EGFR、Her2、GD2、CD19、CD20、CD30、CEA、CA125、PSA和EpCAM,已经在实验和临床研究中得到了巨大的成功。
B7-H3是一种具有免疫球蛋白样结构的跨膜蛋白,属于激活或抑制T细胞应答的B7超家族。B7-H3蛋白在正常组织中表达水平较低,而在许多人类恶性肿瘤中表达水平较高,包括成神经细胞瘤、黑色素瘤和胶质瘤,以及肺癌、胰腺癌、肾癌、结肠癌、卵巢癌、乳腺癌、胃癌、肝细胞癌、结直肠癌、前列腺癌、子宫内膜癌和宫颈癌。大量研究表明,B7-H3对癌症患者的宿主T细胞具有抑制作用,与CTLA-4、Tim-3和PD-1相似,B7-H3被认为是人类共抑制受体,可调节重要的细胞反应,包括细胞增殖、凋亡、粘附和转移,如B7-H3的特异性阻断单克隆抗体MJ18,在胰腺癌模型中显著抑制肿瘤生长;临床上,抗B7-H3单抗8H9应用于神经外胚层肿瘤;抗B7-H3抗体(MGA271)治疗表达B7-H3的多发性难治实体瘤的I期试验正在进行中。总之,这些结果表明B7-H3是免疫抗肿瘤治疗的一个有前途的靶点。
纳米抗体(Nb)是骆驼科动物体内重链抗体(IgG2和IgG3)的可变区域,被称为是自然界存在的最小的抗原结合片段,与传统全长单克隆抗体(mAb,约150KD)相比,Nb具有分子量小(12-15KD),结构更简单,低免疫原性,高组织渗透性、高稳定性、高溶解性和低聚集性以及易于克隆等优点。此外,与mAb同类产品相比,Nb的生产成本显著降低,大多数癌症患者都可以使用。因此应用纳米抗体技术研发一种抗B7-H3纳米抗体的治疗性抗体具有广阔的前景。
发明内容
针对现有技术的上述不足,本发明提供一种抗B7-H3纳米抗体及其应用,该纳米抗体对B7-H3具有特异的识别和结合能力,并有望作为治疗性抗体用于各种B7-H3分子高表达的恶性肿瘤。
本发明提供以下技术方案:
一种抗B7-H3纳米抗体,纳米抗体包括框架区FR和互补决定区CDR,互补决定区CDR包括互补决定区CDR1,互补决定区CDR2和互补决定区CDR3,其中,
互补决定区CDR1的氨基酸序列如SEQ ID NO:2所示,
互补决定区CDR2的氨基酸序列如SEQ ID NO:4所示,
互补决定区CDR3的氨基酸序列如SEQ ID NO:6所示;或者
互补决定区CDR1的氨基酸序列如SEQ ID NO:9所示,
互补决定区CDR2的氨基酸序列如SEQ ID NO:11所示,
互补决定区CDR3的氨基酸序列如SEQ ID NO:13所示;或者
互补决定区CDR1的氨基酸序列如SEQ ID NO:16所示,
互补决定区CDR2的氨基酸序列如SEQ ID NO:18所示,
互补决定区CDR3的氨基酸序列如SEQ ID NO:20所示;或者
互补决定区CDR1的氨基酸序列如SEQ ID NO:23所示,
互补决定区CDR2的氨基酸序列如SEQ ID NO:25所示,
互补决定区CDR3的氨基酸序列如SEQ ID NO:27所示。
进一步地,上述框架区FR包括框架区FR1、框架区FR2、框架区FR3和框架区FR4,其中,
框架区FR1的氨基酸序列SEQ ID NO:1所示,
框架区FR2的氨基酸序列SEQ ID NO:3所示,
框架区FR3的氨基酸序列SEQ ID NO:5所示,
框架区FR4的氨基酸序列SEQ ID NO:7所示;或者
框架区FR1的氨基酸序列SEQ ID NO:8所示,
框架区FR2的氨基酸序列SEQ ID NO:10所示,
框架区FR3的氨基酸序列SEQ ID NO:12所示,
框架区FR4的氨基酸序列SEQ ID NO:14所示;或者
框架区FR1的氨基酸序列SEQ ID NO:15所示,
框架区FR2的氨基酸序列SEQ ID NO:17所示,
框架区FR3的氨基酸序列SEQ ID NO:19所示,
框架区FR4的氨基酸序列SEQ ID NO:21所示;或者
框架区FR1的氨基酸序列SEQ ID NO:22所示,
框架区FR2的氨基酸序列SEQ ID NO:24所示,
框架区FR3的氨基酸序列SEQ ID NO:26所示,
框架区FR4的氨基酸序列SEQ ID NO:28所示。
进一步地,上述抗B7-H3纳米抗体氨基酸序列如SEQ ID NO:29、SEQID NO:30、SEQID NO:31或SEQ ID NO:32所示。
一种DNA分子,编码上述抗B7-H3纳米抗体。
一种表达载体,包含上述DNA分子。
一种宿主细胞,包含上述表达载体。
上述抗B7-H3纳米抗体在制备B7-H3分子检测试剂中的用途。
上述抗B7-H3纳米抗体在制备肿瘤治疗药物中的应用。
本发明的有益效果为:
本发明的抗B7-H3纳米抗体对B7-H3具有特异的识别和结合能力,并有望作为治疗性抗体用于各种B7-H3分子高表达的恶性肿瘤。
具体实施方式
以下通过具体实施例来描述本申请的纳米抗体的具体制备过程,然而本领域的技术人员应当了解,本申请的范围不应受这些实施例的限制,而是包含本领域的技术人员可以做出的各种等同变换形式。
实施例1
(1)动物免疫:首次免疫使用0.5mg B7-H3抗原与弗氏完全佐剂1:1(V:V)混合得到混合液,在骆驼的颈部淋巴结附近左右两侧注射乳化后的混合液成多个包块,跟踪观察皮下注射包块的吸收情况,以确认免疫正确;第二次免疫在首次免疫3周后,使用0.25mg B7-H3抗原与弗氏不完全佐剂1:1(V:V)混合得到混合液,在骆驼的颈部淋巴结附近左右两侧注射乳化后的混合液成多个包块,跟踪观察皮下注射包块的吸收情况,以确认免疫正确;重复第二次免疫方案,进行免疫,重复至第六次;
(2)血清处理和效价检测:在第六次免疫后1周,采集骆驼外周血2mL,分离血清,将人B7-H3重组蛋白包被在ELISA 96孔板中,利用ELISA法测定血清中抗体效价,ELISA结果显示骆驼六免血清效价>1:64000,符合建库标准,表明血清中存在抗人B7-H3的高亲和力抗体;
(3)噬菌体展示免疫抗体库的构建:
①采集骆驼第六次免疫后的外周血50mL,分离淋巴细胞PBMC;取2×107的PBMC,利用RNA提取试剂盒提取总RNA;取5μg RNA,通过RT-PCR反转录试剂盒获得cDNA;
②通过巢式PCR分步获取IgG2和IgG3重链可变区序列,实验步骤如下:
a.设计1对特异性的巢式外侧引物,以cDNA为模板进行第一轮PCR扩增,扩增区域为骆驼重链抗体基因的Leader-CH2区域,产物大小为700bp和900bp;通过DNA凝胶电泳,切胶回收700bp PCR产物;
b.设计巢式内侧引物(5对),以步骤a所得700bp的第一轮PCR产物为模板进行第二轮PCR扩增,扩增区域为骆驼重链抗体可变区VHH片段,产物大小为400bp;使用PCR产物纯化试剂盒对第二轮400bp PCR产物进行纯化回收;
c.通过酶切连接的方式将步骤b所得重链可变区序列VHH插入到经酶切处理的线性化噬菌粒载体VHH-libTemplate中,获得重组载体,经纯化回收后,转化至超级感受态SS320细胞(含辅助噬菌体M13K07);转化后的菌液用SOC培养基重悬并活化1h;取菌液进行10倍比梯度稀释,于LB/tet10及LB/Carb50培养板上涂板,置于37℃生化培养箱过夜;剩余菌液转入2YT/Carb50/Kan25液体培养基中,置于37℃摇床,过夜培养,次日收获上清,加入1/4倍体积的PEG/NaCl溶液,沉淀噬菌体后,取PBT溶液重悬,稀释后即得到噬菌体展示免疫抗体库(-80℃保存备用);
d.统计步骤c所得LB/Carb50平板上克隆数目,骆驼抗体库Lib B7-H3Camel的库容为2.25×109,从平板上各随机挑取20个单克隆测序,结果表明:骆驼抗体库Lib B7H3Camel的VHH插入效率均为94%。
(4)将5μg/mL的人B7-H3重组蛋白加入96孔板(100μL/孔),4℃包被过夜;将NEB5αF’大肠杆菌在2YT/Tet10平板划线生长,37℃孵箱过夜培养;第二天,从2YT/Tet10平板上挑取NEB5αF’单克隆,加入到3mL2YT/Tet10液体培养基中,37℃摇菌生长至OD600=0.8;同时去除96孔板的抗原上清液,每孔加入200μL的1%BSA封闭,同时在空白孔加入200μL1%BSA作为阴性对照孔,在室温下置于3D旋转振荡器2h;去除蛋白孔和对照孔的上清液,用200μLPT清洗,各加入100μL的步骤(3)所得噬菌体抗体库,在室温下置于3D旋转振荡器2h;去除蛋白孔和对照孔的上清液,用200μL PT清洗;向孔中加入100μL 100mM HCl,室温放置5min;将上清液吸出,加入到1.5mL离心管中,使用1M Tris-HCl中和得到混合液,将混合液加入到含1mL NEB5αF’菌的离心管中,摇床37℃,培养1h;取离心管中培养液20μL分别进行10-5、10-6、10-7的稀释,于LB/Carb50培养板上涂板,置于37℃生化培养箱过夜;剩余培养液中加入1μL辅助噬菌体M13K07(终浓度为1010个/mL),摇床37℃,培养1h;将上述培养液转入35mL 2YT/Carb50/Kan25培养液中,置于摇床中,37℃过夜培养,收集噬菌体形成每轮的抗体库;将上述操作重复2轮,至出现噬菌体富集,抗原结合孔在LB/Carb50培养板上的菌落数是阴性对照孔的100倍,富集成功;挑取富集轮的克隆,在96深孔板中扩大培养,离心后使用上清液进行PhageELISA筛选,挑选与人B7-H3重组蛋白结合OD数值:与封闭液结合OD数值>2的克隆,定义为阳性克隆,进行测序和比对,获得Unique序列,如表1所示。
表1生物淘筛获得的纳米抗体和亲和力排序
实验例1
纳米抗体的真核表达:
对实施例1所得4条序列进行真核表达,实验步骤为:
(1)通过PCR分别扩增4条序列的VHH片段,使用酶切连接的方法将VHH片段插入含有hFc标签的真核表达载体pFcIG中,电转入大肠杆菌trans5α宿主菌中,经过博莱霉素筛选,对单克隆测序获得正确的重组质粒;然后扩大培养含重组质粒的宿主菌,使用去内毒素试剂盒获得无菌无内毒素质粒;
(2)用无血清培养基培养HEK293F细胞;使用polyplus悬浮细胞转染试剂将步骤(1)所得重组表达质粒转入HEK293F细胞进行表达,在转染24和72h后加入补料OPM-CHOPFF05,在第5天收集上清,使用Protein A琼脂糖纯化树脂分离纯化抗体,置换保存在PBS的溶液中,4条序列的VHH-hFc重组抗体的293F细胞瞬转表达的产量和SDS-PAGE电泳鉴定结果如表2所示。
表2VHH-hFc重组抗体的真核瞬转表达结果
如表2所示,4条序列的VHH-hFc重组抗体的293F细胞瞬转表达的产量为0.15-29mg/L,SDS-PAGE电泳鉴定:4个抗B7-H3纳米抗体B7H3-1和B7H3-14(结构为:VHH-hFc)的条带大小正常,纯度>95%。
实验例2
实施例1所的抗B7-H3纳米抗体与人B7-H3重组蛋白的亲和力EC50:
使用ELISA法,测定4条序列的VHH-hFc重组抗体与人B7-H3胞外区重组蛋白的亲和力:将人B7-H3胞外区重组蛋白(his标签)加入到ELISA96孔板中,200ng/孔,4℃包被过夜;将VHH-hFc重组抗体进行梯度稀释(0.01μg/mL、1μg/mL、10μg/mL),与抗原进行ELISA反应,使用HRP标记的anti-hIgG1 Fc二抗进行显色,用酶标仪测量450nm处的吸光度值,结果如表3所示。
表3VHH-hFc重组抗体与人B7-H3的ELISA结合EC50
由表3可知,4个抗B7-H3纳米抗体与人B7-H3胞外区重组蛋白的亲和力为EC50=0.24-12.19μg/mL。
以下为纳米抗体的框架区FR氨基酸序列、互补决定区CDR氨基酸序列以及纳米抗体的氨基酸序列。
纳米抗体的氨基酸序列顺序为:框架区FR1,互补决定区CDR1,框架区FR2,互补决定区CDR2,框架区FR3,互补决定区CDR3,框架区FR4。FR1:QVKLVESGGGSVQAGGSLRLSCTASGYDCM(SEQ ID NO:1),
CDR1:A(SEQ ID NO:2),
FR2:WFRQVPGKDREGVA(SEQ ID NO:3),
CDR2:YIDDDRGTNYADSVKG(SEQ ID NO:4),
FR3:RFTISLDNAKNTLYLQMNSLKPEDTAMYYCAA(SEQ ID NO:5),
CDR3:VDCRMHPLPYCDGPYCYGVKY(SEQ ID NO:6),
FR4:WGQGTQVTVSVAHHPEDPSTVESS(SEQ ID NO:7);
FR1:QVQLVESGGGSVQAGGSLRLSCAASGYTYS(SEQ ID NO:8),
CDR1:LYCMG(SEQ ID NO:9),
FR2:WFRQVPGKERDWVA(SEQ ID NO:10),
CDR2:AIATQGDNSGYGDSVKG(SEQ ID NO:11),
FR3:RFTISQDNAKNTVYLQMNSLKPEDTGMYYCAA(SEQ ID NO:12),
CDR3:ARLNCLNIVGVVPADFHY(SEQ ID NO:13),
FR4:WGQGTQVTVSS(SEQ ID NO:14);
FR1:EVKLVQSGGGSVQAGGSLRLSCVASGYTGS(SEQ ID NO:15),
CDR1:RYCMA(SEQ ID NO:16),
FR2:WFREVPWKEREGVA(SEQ ID NO:17),
CDR2:TISTLGGGTYYADSVKG(SEQ ID NO:18),
FR3:RFTISLDNAKNTLYLQMNSLLPEDTAMYYCAA(SEQ ID NO:19),
CDR3:AGGYCSSKVLDRRGFGY(SEQ ID NO:20),
FR4:WGQGTQVTVSS(SEQ ID NO:21);
FR1:QVKLVKSGGGSVQAGESLRLSCVFSGDTFS(SEQ ID NO:22),
CDR1:TYFMA(SEQ ID NO:23),
FR2:WCRQAPGTEREGLA(SEQ ID NO:24),
CDR2:SILRGGGHRYYADSVKD(SEQ ID NO:25),
FR3:RFALSRDAAAKTVYLQMDNLKPDDTAMYYCAA(SEQ ID NO:6),
CDR3:RSRGGTWSFLNSNDYDY(SEQ ID NO:27),
FR4:WGQGTQVAVSS(SEQ ID NO:28)。
纳米抗体B7H3-1:
QVKLVESGGGSVQAGGSLRLSCTASGYDCMAWFRQVPGKDREGVAYIDDDRGTNYADSVKGRFTISLDNAKNTLYLQMNSLKPEDTAMYYCAAVDCRMHPLPYCDGPYCYGVKYWGQGTQVTVSVAHHPEDPSTVESS(SEQIDNO:29);
纳米抗体B7H3-14:
QVQLVESGGGSVQAGGSLRLSCAASGYTYSLYCMGWFRQVPGKERDWVAAIATQGDNSGYGDSVKGRFTISQDNAKNTVYLQMNSLKPEDTGMYYCAAARLNCLNIVGVVPADFHYWGQGTQVTVSS(SEQ ID NO:30);
纳米抗体B7H3-7:
EVKLVQSGGGSVQAGGSLRLSCVASGYTGSRYCMAWFREVPWKEREGVATISTLGGGTYYADSVKGRFTISLDNAKNTLYLQMNSLLPEDTAMYYCAAAGGYCSSKVLDRRGFGYWGQGTQVTVSS(SEQ ID NO:31);
纳米抗体B7H3-25:
QVKLVKSGGGSVQAGESLRLSCVFSGDTFSTYFMAWCRQAPGTEREGLASILRGGGHRYYADSVKDRFALSRDAAAKTVYLQMDNLKPDDTAMYYCAARSRGGTWSFLNSNDYDYWGQGTQVAVSS(SEQ ID NO:32)。
Claims (8)
1.一种抗B7-H3纳米抗体,其特征在于,所述纳米抗体包括框架区FR和互补决定区CDR,所述互补决定区CDR包括互补决定区CDR1,互补决定区CDR2和互补决定区CDR3,其中,
所述互补决定区CDR1的氨基酸序列如SEQ ID NO:2所示,其氨基酸序列为A,
所述互补决定区CDR2的氨基酸序列如SEQ ID NO:4所示,
所述互补决定区CDR3的氨基酸序列如SEQ ID NO:6所示;或者
所述互补决定区CDR1的氨基酸序列如SEQ ID NO:9所示,
所述互补决定区CDR2的氨基酸序列如SEQ ID NO:11所示,
所述互补决定区CDR3的氨基酸序列如SEQ ID NO:13所示;或者
所述互补决定区CDR1的氨基酸序列如SEQ ID NO:16所示,
所述互补决定区CDR2的氨基酸序列如SEQ ID NO:18所示,
所述互补决定区CDR3的氨基酸序列如SEQ ID NO:20所示;或者
所述互补决定区CDR1的氨基酸序列如SEQ ID NO:23所示,
所述互补决定区CDR2的氨基酸序列如SEQ ID NO:25所示,
所述互补决定区CDR3的氨基酸序列如SEQ ID NO:27所示。
2.根据权利要求1所述的抗B7-H3纳米抗体,其特征在于,所述框架区FR包括框架区FR1、框架区FR2、框架区FR3和框架区FR4,其中,
所述框架区FR1的氨基酸序列SEQ ID NO:1所示,
所述框架区FR2的氨基酸序列SEQ ID NO:3所示,
所述框架区FR3的氨基酸序列SEQ ID NO:5所示,
所述框架区FR4的氨基酸序列SEQ ID NO:7所示;或者
所述框架区FR1的氨基酸序列SEQ ID NO:8所示,
所述框架区FR2的氨基酸序列SEQ ID NO:10所示,
所述框架区FR3的氨基酸序列SEQ ID NO:12所示,
所述框架区FR4的氨基酸序列SEQ ID NO:14所示;或者
所述框架区FR1的氨基酸序列SEQ ID NO:15所示,
所述框架区FR2的氨基酸序列SEQ ID NO:17所示,
所述框架区FR3的氨基酸序列SEQ ID NO:19所示,
所述框架区FR4的氨基酸序列SEQ ID NO:21所示;或者
所述框架区FR1的氨基酸序列SEQ ID NO:22所示,
所述框架区FR2的氨基酸序列SEQ ID NO:24所示,
所述框架区FR3的氨基酸序列SEQ ID NO:26所示,
所述框架区FR4的氨基酸序列SEQ ID NO:28所示;
所述氨基酸序列SEQ ID NO:1,3,5,7与氨基酸序列SEQ ID NO:2,4,6组成抗B7-H3纳米抗体;或
所述氨基酸序列SEQ ID NO:8,10,12,14与氨基酸序列SEQ ID NO:9,11,13组成抗B7-H3纳米抗体;或
所述氨基酸序列SEQ ID NO:15,17,19,21与氨基酸序列SEQ ID NO:16,18,20组成抗B7-H3纳米抗体;或
所述氨基酸序列SEQ ID NO:22,24,26,28与氨基酸序列SEQ ID NO:23,25,27组成抗B7-H3纳米抗体。
3.根据权利要求1所述的抗B7-H3纳米抗体,其特征在于,所述抗B7-H3纳米抗体的氨基酸序列如SEQ ID NO:29、SEQ ID NO:30、SEQ ID NO:31或SEQ ID NO:32所示。
4.一种DNA分子,其特征在于,编码如权利要求1~3任一项所述的抗B7-H3纳米抗体。
5.一种表达载体,其特征在于,包含权利要求4所述的DNA分子。
6.一种宿主细胞,其特征在于,包括权利要求5所述的表达载体。
7.权利要求1~3任一项所述的抗B7-H3纳米抗体在制备人源B7-H3分子检测试剂中的用途。
8.权利要求1~3任一项所述的抗B7-H3纳米抗体在制备人类肿瘤治疗药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211731515.XA CN116239691B (zh) | 2022-12-30 | 2022-12-30 | 一种抗b7-h3纳米抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211731515.XA CN116239691B (zh) | 2022-12-30 | 2022-12-30 | 一种抗b7-h3纳米抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116239691A CN116239691A (zh) | 2023-06-09 |
CN116239691B true CN116239691B (zh) | 2024-04-02 |
Family
ID=86632217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211731515.XA Active CN116239691B (zh) | 2022-12-30 | 2022-12-30 | 一种抗b7-h3纳米抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116239691B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110642948A (zh) * | 2019-10-09 | 2020-01-03 | 达石药业(广东)有限公司 | B7-h3纳米抗体、其制备方法及用途 |
CN115819593A (zh) * | 2022-12-30 | 2023-03-21 | 兰州大学第二医院 | 一种抗cd73纳米抗体及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114729041A (zh) * | 2019-10-22 | 2022-07-08 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗多种实体瘤的靶向b7h3(cd276)的高亲和力纳米抗体 |
-
2022
- 2022-12-30 CN CN202211731515.XA patent/CN116239691B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110642948A (zh) * | 2019-10-09 | 2020-01-03 | 达石药业(广东)有限公司 | B7-h3纳米抗体、其制备方法及用途 |
CN115819593A (zh) * | 2022-12-30 | 2023-03-21 | 兰州大学第二医院 | 一种抗cd73纳米抗体及其应用 |
Non-Patent Citations (2)
Title |
---|
Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia;Lichtman EI等;《Clin Cancer Res.》;20210601;第27卷(第11期);3141-3153 * |
急性白血病中共刺激分子B7-H3(CD276)的表达特点及其预后价值;张蔚等;《第四届全国血液肿瘤学术大会暨第七届全国淋巴肿瘤诊治进展研讨会论文汇编》;20141231;全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN116239691A (zh) | 2023-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108250296B (zh) | 全人源抗人pd-l1单克隆抗体及其应用 | |
WO2020155310A1 (zh) | 一种新型scFv氨基酸序列、包含其的嵌合抗原受体及其应用 | |
CN108285485B (zh) | 一种抗pd-1的单域抗体及其应用 | |
CN113105548B (zh) | 抗ceacam5纳米抗体 | |
CN110642951B (zh) | 一种抗ca125糖类抗原的高中和活性纳米抗体及其应用 | |
CN110372793B (zh) | Pd-l1的纳米抗体及其临床应用 | |
CN114262377B (zh) | 一种阻断cd70与其配体cd27结合的抗人cd70纳米抗体的制备方法及其编码序列 | |
US20210246220A1 (en) | Anti-BCMA single-chain antibody scFv and preparation method and application thereof | |
CN117069844B (zh) | 包含特定等电点的抗人bcma纳米抗体的双特异性抗体及应用 | |
CN116239691B (zh) | 一种抗b7-h3纳米抗体及其应用 | |
CN114057880B (zh) | 一种dll3单克隆抗体 | |
CN110396128B (zh) | 抗cd19纳米抗体的制备 | |
CN115819593A (zh) | 一种抗cd73纳米抗体及其应用 | |
EP3782644A1 (en) | Anti-erbb2 single chain antibody, human erbb2-targeting chimeric antigen receptor, recombinant vector, recombinant cell, and application thereof | |
CN114106187B (zh) | 一种靶向ogt的特异性鲨鱼单域抗体及其制备方法和应用 | |
CN113501873B (zh) | Rbv的蛋白结合分子及其用途 | |
CN111057154B (zh) | 基于驼源Fc片段的免疫原的制备及应用 | |
CN116262786A (zh) | 针对folr1的单域抗体及其衍生蛋白和应用 | |
CN112250765A (zh) | 一种针对her2的纳米抗体及其应用 | |
CN114369163B (zh) | 与人血小板衍生生长因子受体β结合的羊驼源纳米抗体 | |
WO2024061364A1 (zh) | 一种抗4-1bb纳米抗体及其制备和应用 | |
CN114044826B (zh) | 针对EGFRvIII的单域抗体及其衍生蛋白和应用 | |
CN114409792B (zh) | 抗EphB4纳米抗体 | |
CN116023492A (zh) | 一种阻断pd1与pdl1结合的抗人pdl1纳米抗体的制备方法及其编码序列 | |
CN117820484A (zh) | 抗cd5纳米抗体及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |